ClinicalTrials.gg
RecruitingNCT07375147Updated May 22, 2026

Transanal vs Transvaginal Rectal Resection for Anterior Rectocele

An interventional study of Stapled Transanal Rectal Resection and Stapled Transvaginal Rectal Resection in Rectocele; Female, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2025, registered Jan 2026).
  • Started Jun 2025; still recruiting 1 year 4 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Female patients presenting with obstructed defecation syndrome due to anterior rectocele will be screened according to inclusion and exclusion criteria. Eligible patients will undergo clinical assessment and appropriate investigations including defecography. After informed consent, patients will be randomized into two groups: Stapled Transanal rectal resection or Stapled Transvaginal rectal resection. Improvement in obstructed defecation symptoms and postoperative complications will be compared between the two groups.

Read the detailed description

This is a randomized controlled trial aims to compare the clinical outcomes of Stapled Transanal versus Stapled Transvaginal rectal resection in female patients with obstructed defecation syndrome (ODS) caused by anterior rectocele.

Female patients presenting to the outpatient colorectal clinic with symptoms of obstructed defecation syndrome will be screened for eligibility according to predefined inclusion and exclusion criteria. All eligible patients will receive a detailed explanation of the study objectives, procedures, potential benefits, and risks. Written informed consent will be obtained prior to enrollment.

A comprehensive preoperative evaluation will be performed for all participants, including detailed medical history, physical and anorectal examination, and appropriate investigations including defecography to confirm the diagnosis and assess the severity of rectocele.

Enrolled patients will be randomly assigned in a 1:1 ratio into one of two intervention groups. Group A will undergo stapled Transanal rectal resection, while Group B will undergo stapled transvaginal rectal resection. All surgical procedures will be performed by experienced colorectal surgeons.

Primary outcome measures will include improvement in obstructed defecation symptoms as assessed by Cleveland Clinic Constipation (CCC) score. Secondary outcomes will include length of hospital stay, operative time, postoperative pain score, postoperative continence state, Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) and postoperative complications.

02

Conditions studied

  • Rectocele; Female

Browse trials for

Keywords

  • Rectocele
  • Obstructed defecation
  • Stapled Transanal Rectal Resection
  • Stapled Transvaginal Rectal Resection
03

In context

Rectocele

50 studies on the registry are indexed under Rectocele; 9 are open to participants now.

This study's planned enrollment of 62 is close to the median of 62 across 37 interventional studies indexed under Rectocele.

Browse Rectocele studies →

Lead sponsor

Cairo University is the lead sponsor of 4,941 studies on the registry; 1,458 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult female patients complaining of obstructed defecation syndrome with anterior rectocele ≥ 3 cm on straining with failure of conservative management.

Exclusion criteria

Exclusion Criteria:

  • Patients with Slow-transit constipation
  • Patients with rectocele of \< 3 cm on straining
  • Patients with complete external rectal prolapse
  • Evidence of colorectal carcinoma or Inflammatory bowel disease ( IBD)
  • Previous rectal surgeries
  • Inability for lifestyle change postoperatively
  • Previous surgeries for anterior rectocele
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Stapled Transanal Rectal Resection

    Patients in this group will be conducted to Stapled Transanal rectal resection for the anterior rectocele

    Procedure: Stapled Transanal Rectal Resection

  • Experimental
    Stapled Transvaginal Rectal Resection

    patients in this group will be conducted to stapled transvaginal rectal resection for the anterior rectocele

    Procedure: Stapled Transvaginal Rectal Resection

Interventions

  • ProcedureStapled Transanal Rectal Resection

    Patients were placed in the lithotomy position. Using the trans-anal approach, rectocele was done using PPH circular staplers. A circular anal dilator (CAD) was inserted into the anus and sutured into position. Three full-thickness prolene 2/0 sutures were positioned at the anterior, left anterior lateral, and right anterior lateral locations, approximately 4 cm above the dentate line. At the posterior aspect, a tongue depressor was placed into the CAD groove to protect the posterior rectal wall. After insertion of the Procedure for Prolapse and Hemorrhoids stapler (PPH stapler) into the rectum with its head open past the proximal suture, PPH stapler was progressively closed. Per vaginal examination was done To make sure the stapler did not include the vagina. The stapler was then fired to complete the anterior rectal resection.

  • ProcedureStapled Transvaginal Rectal Resection

    The patient in the lithotomy position. Anal dilatation was performed. A transverse incision was made in the mucocutaneous border of the vaginal introitus; the posterior vaginal wall was dissected and separated from the anterior rectal wall up to the posterior fornix. Dissection was extended laterally to the maximum length of the rectocele. Two Babcock clamps were applied longitudinally to the rectocele, and the stapler was fired to divide the rectocele. Partial thickness stitches were applied over the staple line using vicryl 2/0 suture to reinforce the staple line.

06

What researchers measure

Primary outcomes

  1. Improvement in obstructed defecation symptoms in both groups using Cleveland Clinic Constipation (CCC) score

    Compare Improvement in obstructed defecation symptoms in both groups using Cleveland Clinic Constipation (CCC) score. CCC score ranges from 0 to 30. Higher scores indicate a worse outcome (more severe obstructed defecation symptoms )

    Time frame: Up to 6 months postoperatively

Secondary outcomes

  1. Operative time

    Compare time of operation between both procedure

    Time frame: During surgery

  2. Hospitalization period

    Compare how many days patients stay in hospital in both groups

    Time frame: From date of hospital admission until date of hospital discharge, assessed up to 10 days after surgery

  3. surgical site infection

    compare surgical site infection in both groups

    Time frame: Up to 6 months postoperatively

  4. Time for wound Healing

    Time for wound Healing in both groups

    Time frame: Up to 6 months postoperatively

  5. Postoperative bleeding

    Compare Postoperative bleeding in both groups

    Time frame: Up to 6 months postoperatively

  6. Postoperative fecal incontinence

    Compare post postoperative fecal incontinence in both groups

    Time frame: Up to 6 months postoperatively

  7. Postoperative urine retention

    Compare postoperative urine retention in both groups

    Time frame: Within 48 hours postoperatively

  8. Pain intensity

    Compare Pain intensity measured using Visual Analogue Scale between both groups (Visual Analogue Scale for Pain: ranges from 0 to 10 . Higher scores indicate a worse outcome {greater pain intensity})

    Time frame: At day 1 and day 7 postoperatively

  9. Sexual Function in both groups

    Compare sexual function in both groups using Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ- 12). PISQ-12 score ranges from 0 to 48. Higher scores indicate better sexual function

    Time frame: Up to 6 months postoperatively

  10. Postoperative anal stenosis in both groups

    Postoperative anal stenosis will be assessed by digital rectal examination and graded clinically as follows: * Mild: anal canal admits a well lubricated index finger. * Moderate: Forceful dilatation required to admit a well lubricated index finger. * Severe: Little finger cannot be admitted without forceful dilatation

    Time frame: Up to 6 months postoperatively

  11. Postoperative rectovaginal fistula in both groups

    Postoperative rectovaginal fistula will be assessed using the following methods: * History: Passage of flatus or stool from the vagina. * Clinical examination: Digital rectal examination and per vaginal examination to detect induration or fistula opening. * MRI of the pelvis: Performed if fistula is suspected based on history or clinical examination to confirm the diagnosis.

    Time frame: Up to 6 months postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because this is a small surgical trial with a limited number of participants, and sharing raw data could lead to identification of participants

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 18 months after the start.

Of 16 interventional studies with no phase under Rectocele, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 38. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 29, 2026
StartActual
Jun 14, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07375147
Lead sponsor
Cairo University
Responsible party
Ahmed Mohamed Abdelaal (Lecturer, Cairo University) — Principal investigator
First posted
Jan 29, 2026
Start date
Jun 14, 2025
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Ahmed Mohamed Abdelaal, Lecturer
Contact
drabdelaal90@gmail.com
+201118732767
Mohamed Tamer, lecteurer
study director · Cairo University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion